Institutional Ownership: A Key Indicator for Arrowhead Pharmaceuticals' Stock Performance
ByAinvest
Monday, Sep 1, 2025 6:39 am ET1min read
ARWR--
The company's stock experienced a 6.4% increase last week, despite a 7.6% one-year loss, indicating that institutional investors are bullish on the company's prospects. The largest shareholder is BlackRock, Inc., which owns 14% of the shares, followed by other notable institutional investors such as Vanguard Group and T. Rowe Price Investment Management Inc. [1].
Analyst forecasts also suggest a strong business outlook for Arrowhead Pharmaceuticals. The company's stock has been covered by several analysts, with a mix of "buy" and "strong-buy" ratings, indicating optimism about the company's future performance. Despite recent earnings missing analyst expectations, the company's revenue and earnings per share (EPS) have shown signs of improvement [2].
Institutional ownership and analyst forecasts provide valuable insights into Arrowhead Pharmaceuticals' prospects. However, investors should also consider other factors, such as the company's earnings history and financial health, when making investment decisions. The company's stock has a market capitalization of $2.95 billion, a P/E ratio of -16.66, and a beta of 0.94, indicating a relatively low risk compared to the broader market [2].
References:
[1] https://finance.yahoo.com/news/arrowhead-pharmaceuticals-inc-nasdaq-arwr-101903529.html
[2] https://www.marketbeat.com/instant-alerts/filing-pale-fire-capital-se-takes-position-in-arrowhead-pharmaceuticals-inc-arwr-2025-08-24/
Arrowhead Pharmaceuticals' stock price is sensitive to institutional trading actions, with a total of 8 investors holding 51% ownership. Analyst forecasts and ownership data suggest a strong business prospect. Institutional investors, who own 69% of the company, experienced a 6.4% increase in share price last week despite a 7.6% one-year loss.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has seen significant institutional involvement in its stock, with a total of 8 investors holding 51% ownership. This high level of institutional ownership makes the stock price particularly sensitive to trading actions by these investors [1].The company's stock experienced a 6.4% increase last week, despite a 7.6% one-year loss, indicating that institutional investors are bullish on the company's prospects. The largest shareholder is BlackRock, Inc., which owns 14% of the shares, followed by other notable institutional investors such as Vanguard Group and T. Rowe Price Investment Management Inc. [1].
Analyst forecasts also suggest a strong business outlook for Arrowhead Pharmaceuticals. The company's stock has been covered by several analysts, with a mix of "buy" and "strong-buy" ratings, indicating optimism about the company's future performance. Despite recent earnings missing analyst expectations, the company's revenue and earnings per share (EPS) have shown signs of improvement [2].
Institutional ownership and analyst forecasts provide valuable insights into Arrowhead Pharmaceuticals' prospects. However, investors should also consider other factors, such as the company's earnings history and financial health, when making investment decisions. The company's stock has a market capitalization of $2.95 billion, a P/E ratio of -16.66, and a beta of 0.94, indicating a relatively low risk compared to the broader market [2].
References:
[1] https://finance.yahoo.com/news/arrowhead-pharmaceuticals-inc-nasdaq-arwr-101903529.html
[2] https://www.marketbeat.com/instant-alerts/filing-pale-fire-capital-se-takes-position-in-arrowhead-pharmaceuticals-inc-arwr-2025-08-24/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet